ClinicalTrials.gg
WithdrawnNCT07084831SHINEUpdated Oct 30, 2026

A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

A Phase 3 interventional study of Xanomeline/trospium in Schizophrenia; Psychosis and Cognitive Impairment, sponsored by European Group for Research In Schizophrenia. Withdrawn at 16 sites in 10 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by European Group for Research In Schizophrenia · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
Ethical committee in Europe did not provide approval
Updated Oct 30, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Enrollment
20th of 20
0 · median 178
Started
2027
the only one that year
Phase 3
14 of 20
4 open now
Registered
15th of 20
by date
Lead sponsor
1 of 20
European Group for Research In Schizophrenia

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 20th largest by enrollment, is the only one that started in 2027, is one of 14 in phase 3, and was the 15th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

Schizophrenia is a long-lasting and serious mental health disorder that affects about 1% of people worldwide. It can cause symptoms such as hallucinations and delusions (called positive symptoms), confused or disorganized thinking, reduced motivation and emotional expression (negative symptoms), difficulties with memory and concentration (cognitive symptoms), and movement problems like restlessness or slowed activity. Current treatments, called antipsychotics, mainly work by blocking dopamine in the brain. These medicines are helpful for hallucinations and delusions, but they do little to improve negative or cognitive symptoms.

A new medicine, Xanomeline/Trospium (XT), works differently. It targets a brain system called the muscarinic acetylcholine receptors while limiting side effects elsewhere in the body. Clinical trials have shown that XT reduces psychotic symptoms effectively and is generally well tolerated. The FDA approved XT in 2024 for adults with schizophrenia. Importantly, early results also suggest that XT may help improve thinking and memory (cognition domains), though this has not yet been studied in depth.

Most schizophrenia drug studies pay little attention to long-term changes in cognition, often using only short screening tests. This study will be the first to take a deep look at cognitive function over a full year of XT treatment. It will also examine how changes in thinking skills connect with other aspects of life, such as symptom control, daily functioning, and quality of life. By making cognition a central outcome, the study responds to an urgent need in schizophrenia research: moving beyond just controlling hallucinations and delusions toward improving real-world recovery. The results could help shape future treatment strategies and support the idea that cognition should be a core treatment target in schizophrenia.

Read the detailed description

This is a phase III, prospective, open-label, single-arm, international, multicenter study. At visit 1, the informed consent is signed and screening is performed to confirm eligibility. At visit 2, baseline measures are performed, and the new treatment is initiated. Max. 14 days after the baseline visit, the pre-study antipsychotic treatment is withdrawn via tapering. At visit 3, 4, 5, 7 and 9 participants' general wellbeing and safety is assessed. At visit 6, 8 and 10, baseline measures are repeated. Between visit 6-7, visit 7-8, visit 8-9 and visit 9-10, a phone call is planned to assess general psychopathology, adverse events and concomitant medication. The treatment duration is one year for each participant; with a safety follow up 4 weeks after the end of the trial. All participants are treated with XT open label.

03

Conditions studied

  • Schizophrenia; Psychosis
  • Cognitive Impairment

Keywords

  • functioning
  • quality of life
  • speech analyses
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be between 18 and 55 years of age.
  2. Be willing and able to provide , after the nature of the study has been fully explained. This includes being able to understand the locally approved informed consent (and information letter) in the local language.
  3. Have a current diagnosis of schizophrenia, which needs to be confirmed by MINI.
  4. Have all PANSS positive items + G8 and G10 ≤4 at screening.
  5. Be on a stable dose of oral antipsychotic medication(s) for at least 4 weeks prior to Screening. Participants should be on monotherapy oral AP for baseline visit.
  6. Have a SCIP total below 70.
  7. Test negative for pregnancy at the screening visit and must be using a highly effective method during the study and 30 days after the study, if being a female of .

Exclusion criteria

Exclusion criteria:

  1. Be pregnant, lactating, or less than 3 months postpartum.
  2. Be at significant risk of committing suicide. This is defined as: participants with active suicidal ideation with some intent to act, without specific plan ("Yes" to question 4 of the Columbia-Suicide Severity Rating Scale (C-SSRS) or active suicidal ideation with specific plan and intent ("Yes" to question 5 of the C-SSRS), followed by an assessment by the treating clinician who determines it is not safe for the participant to participate in the study.
  3. Currently meet criteria for a manic episode or major depressive disorder as confirmed by the MINI.
  4. Currently meeting DSM-5 criteria for severe substance and/or alcohol use disorder as confirmed by the MINI (≥6 on module K for alcohol use disorder and/or ≥6 on module J for substance use disorder, unless being in early or sustained remission).
  5. Have a positive urine toxicology for phencyclidine, amphetamines, opiates (unless participant has a valid prescription for short-term use), cocaine, or alcohol ( alcohol use in the opinion of the Investigator). Nicotine and caffeine use is allowed. Stimulants and cannabis is allowed when used sporadically and recreationally as per the judgement of the clinician.
  6. Present with an intellectual disability, drug-induced psychosis, or history of clinically significant brain trauma as per the judgement of the clinician.
  7. Have current or past use of clozapine (used for at least 6 weeks in an effective dose range) and/or current use of a long-acting injectable antipsychotic, or anticholinergic treatment that cannot be discontinued before the baseline visit.
  8. Be expected to require more than the allowed psychotropic concomitant medication during the study (from baseline on). This is defined as: needing benzodiazepines of more than 2 mg lorazepam equivalent (daily), quetiapine, antidepressants, mood stabilizers or benzodiazepines at a dose exceeding the allowed threshold. If these treatments are used at the screening visit, they must be tapered down before the baseline visit.
  9. Have clinically significant abnormal finding on the physical examination, medical history, (at screening), or clinically significant laboratory results at screening.
  10. Participated in any cognitive remediation/training program or completed the BACS within 4 weeks of Screening.
  11. Having a known allergy to xanomeline, trospium chloride or any of the ingredients of XT.
  12. Have current presence of clinically significant cardiovascular, pulmonary, renal, hematologic, gastrointestinal (e.g., obstructive disorders [including conditions that may decrease GI motility, such as ulcerative colitis, intestinal atony, and myasthenia gravis], endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results. This includes:

12a. Have history or high risk of urinary retention. 12b. All grades of hepatic impairment (mild [ Class A], moderate [Child-Pugh Class B], and severe [Child-Pugh Class C]).

12c. Elevations in hepatic transaminases at screening ≥ 2× for and AST and/or > 2 × ULN, unless in the context of Gilbert's syndrome.

12d. Have a history or high risk for narrow-angle glaucoma. 12e. Active biliary disease (e.g., symptomatic gallstones). Participants with other biliary histories are eligible and should be discussed with the sponsor.

12f. Participants with a history of bladder stones . 12g. Participants with a history of recurrent urinary tract infections. 12h. For all male participants, serum prostate-specific antigen >10 ng/mL at screening.

12i. For male participants ≥ 45 years of age, an IPSS score of 5 (i.e, "almost always") on items 1, 3, 5, or 6, and/or for male participants ≥ 45 years of age, an IPSS score ≥ 9 for the sum of items 1, 3, 5, and 6.

12j. An of \< 60 mL/min (which indicates renal dysfunction). 12k. History of unstable hypertension or tachycardia as evidenced by a blood pressure of ≥ 160/100 mmHg at screening and/or a heart rate of ≥ 110 bpm at screening.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Xanomeline/trospium

    Xanomeline/trospium that is provided to all participants

    Drug: Xanomeline/trospium

Interventions

06

What researchers measure

Primary outcomes

  1. Change in cognitive performance after 24 weeks of treatment, relative to baseline.

    The within-participant change in the Brief Assessment of Cognition in Schizophrenia composite cognitive score from baseline to follow-up after 24 weeks. Higher score means better cognition. There is no max score, as the tests have different scoring methods (number correct, reaction time).

    Time frame: 24 weeks

Secondary outcomes

  1. Change in negative symptoms after 24 weeks of treatment, relative to baseline.

    The within-participant change in the Positive And Negative Syndrome Scale (PANSS) negative subscale from baseline to follow-up after 24 weeks. A higher score means more schizophrenia-related symptoms. The maximum score is 49.

    Time frame: 24 weeks

Other outcomes

  1. Change in Functional Skills assessment and training (FUNSAT) scores for ATM banking, ticket kiosk, and medication management after 12, 24 and 52 weeks of treatment, relative to baseline.

    The within-participant change in the Functional Skills assessment and training (FUNSAT) scores for ATM banking, ticket kiosk and medication management from baseline to follow-up after 12, 24 and 52 weeks. Higher reaction time scores means worse functioning (without maximum), higher number correct means better functioning

    Time frame: 12, 24 and 52 weeks

  2. Change in Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS) between baseline and week 24

    The within-participant change in Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS) between baseline and week 24. A higher score means better subjective and social cognition.

    Time frame: 24 weeks

  3. Change in Subjective Scale to Investigate Social Cognition Scale scores (MRMET) between baseline and week 24

    The within-participant change in Social Cognition Scale scores (MRMET) between baseline and week 24. A higher score means better subjective and social cognition.

    Time frame: 24 weeks

  4. Change in Brief Assessment of Cognition in Schizophrenia (BACS) scores between baseline to week 12 and week 52.

    The within-participant change in Brief Assessment of Cognition in Schizophrenia (BACS) scores between baseline to week 12 and week 52. Higher score means better cognition.There is no max score, as the tests have different scoring methods (number correct, reaction time).

    Time frame: Week 12 and 52

  5. Change in the Positive And Negative Syndrome Scale (PANSS) Negative Subscale Factor from baseline to week 12 and week 52

    Within-participant change in the Positive And Negative Syndrome Scale (PANSS) Negative Subscale Factor from baseline to week 12 and week 52. A higher score means more schizophrenia-related symptoms. The maximum score is 49.

    Time frame: Week 12 and 52

  6. Change in the Brief Negative Symptom Scale (BNSS) and Self-report of Negative Symptoms (SNS) scores from baseline to week 24 and week 52.

    Within-participant change in the Brief Negative Symptom Scale (BNSS) and Self-report of Negative Symptoms (SNS) scores from baseline to week 24 and week 52. A higher score on BNSS means more negative symptoms. The maximum score is 78. A higher score on SNS means more negative symptoms. The maximum score is 40.

    Time frame: week 24 and 52

  7. Change in the Positive And Negative Syndrome Scale (PANSS) Total and Positive Subscale scores from baseline to week 12; week 24 and week 52.

    Within-participant change in the Positive And Negative Syndrome Scale (PANSS)Total and Positive Subscale scores from baseline to week 12; week 24 and week 52. A higher score means more schizophrenia-related symptoms. The PANSS total score has a maximum of 210, while the positive scale has a maximum of 49.

    Time frame: Week 12, 24 and 52

  8. Change in safety assessments from baseline to week 4; week 12; week 24 and week 52

    Within-participant change in safety assessments from baseline to week 4; week 12; week 24 and week 52. This is defined as the occurence of AEs during the study. The is no minimum or maximum.

    Time frame: week 4, 12, 24 and 52

  9. Change in the physical examination (blood pressure (systolic/diastolic))

    Within-participant change in the physical examination in the blood pressure (systolic/diastolic)) from baseline to week 12; week 24 and week 52.

    Time frame: week 12, 24 and 52

  10. Change in the physical examination (heart rate)

    Within-participant change in the physical examination in the heart rate from baseline to week 12; week 24 and week 52.

    Time frame: week 12, 24 and 52

  11. Change in the physical examination( weight)

    Within-participant change in the physical examination in the weight from baseline to week 12; week 24 and week 52.

    Time frame: week 12, 24 and 52

  12. Change in the physical examination (examination organ systems)

    Within-participant change in the physical examination in the examination organ systems from baseline to week 12; week 24 and week 52.

    Time frame: week 12, 24 and 52

  13. Change in the physical examination(blood pressure, heart, rate, weight, examination organ systems)

    Within-participant change in the physical examination (blood pressure, heart, rate, weight, examination organ systems) from baseline to week 12; week 24 and week 52.

    Time frame: week 12, 24 and 52

  14. Change in the Simpson Angus Scale (SAS) from baseline to week 12; week 24 and week 52.

    Within-participant change in the Simpson Angus Scale (SAS) from baseline to week 12; week 24 and week 52. Higher scores on the SAS (max 40), means that the participants has more adverse events

    Time frame: week 12, 24 and 52

  15. Change in the Barnes Akathisia Rating Scale (BARS) from baseline to week 12; week 24 and week 52.

    Within-participant change in the Barnes Akathisia Rating Scale (BARS) from baseline to week 12; week 24 and week 52. Higher scores on the BARS (max 14) mean more adverse events.

    Time frame: week 12, 24 and 52

  16. Change in the UKU Side Effect Rating Scale from baseline to week 12; week 24 and week 52.

    Within-participant change in the UKU Side Effect Rating Scale from baseline to week 12; week 24 and week 52. Higher scores on the UKU (max 144) mean more adverse events.

    Time frame: week 12, 24 and 52

  17. Change in the ASSIST from baseline to week 12; week 24 and week 52.

    Within-participant change in the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) from baseline to week 12; week 24 and week 52. H More items ticked on the ASSIST means that the participants has more addictions.

    Time frame: week 12, 24 and 52

  18. Incidence of treatment emergent adverse events (TEAE) defined as incidence of AEs observed from started of treatment initiation until the end of safety follow-up visit.

    Incidence of treatment emergent adverse events (TEAE) defined as incidence of AEs observed from started of treatment initiation until the end of safety follow-up visit, will also be summarized by system organ class and preferred term (MedDRA). Serious TEAEs and TEAEs leading to study treatment discontinuation will also be summarized by system organ class and preferred term..

    Time frame: Week 4, 12, 24, 52

  19. Change in the Calgary Depression Scale for Schizophrenia (CDSS) total score from baseline to week 24 and week 52.

    Within-participant Change in the Calgary Depression Scale for Schizophrenia (CDSS) total scores from baseline to week 24 and week 52. Higher scores means more depressive symptoms. The maximum score is 27.

    Time frame: week 24 and 52

  20. Change in the Clinical Global Impression-Severity/Improvement and Patient Glocal Impression-Severity/Improvement scores from baseline to week 12; week 24 and week 52.

    Within-participant Change in the CGI-S/I and PGI-S/I scores from baseline to week 12; week 24 and week 52. Higher scores mean more symptom servity and less improvement. there are 4 questions in total. For the 2 S=severity questions, higher scores (max score: 7) means higher symptoms severity. For the 1 I=improvement questions, higher scores (max score: 7) mean less improvement

    Time frame: week 12, 24 and 52

  21. Change in the Personal and Social Performance Scale (PSP) total and subscale scores from baseline to week 24 and week 52

    Within-participant change in the Personal and Social Performance Scale (PSP) total and subscale scores from baseline to week 24 and week 52. A higher total score means better performance (max score: 100). A lower score on the subquestions means less problems in functioning (max score: 24).

    Time frame: week 24 and 52

  22. Change in the Manchester Short Assessment of Quality of Life (MANSA) total score from baseline to week 24 and week 52.

    Within-participant change in the Manchester Short Assessment of Quality of Life (MANSA)total score from baseline to week 24 and week 52. A higher score means better quality of life ans satisfaction. The maximum score is 112.

    Time frame: week 24 and 52

  23. Change in speech characteristics from baseline to week 24 and week 52

    Within-participant change in speech characteristics from baseline to week 24 and week 52. This is analysed via speech NLP pipelines in 2 recordings of each participant that consented.

    Time frame: week 24 and 52

07

Study locations

16 sites
  • Medical University Innsbruck
    Innsbruck, 6020, Austria
  • UPC KU Leuven
    Leuven, 3070, Belgium
  • National Institute of Mental Health
    Klecany, 250 67, Czechia
  • Psykiatrisk Center Glostrup
    Glostrup Municipality, 2600, Denmark
  • University of Augsburg
    Augsburg, 86156, Germany
  • University Hospital Cologne
    Cologne, 50937, Germany
  • Central Institute of Mental Health
    Mannheim, 68159, Germany
  • Ludwig Maximilian University
    München, 80336, Germany
  • Semmelweis University
    Budapest, 1083, Hungary
  • Sheba Medical Center
    Ramat Gan, Israel
  • University of Campania Luigi Vanvitelli
    Naples, 80138, Italy
  • AOU Città della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • University Medical Center Groningen
    Groningen, Netherlands
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Virgen del Rocío
    Seville, 41013, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Our Publication Policy is as follows: researchers can submit a request to receive the data. The Study Management Team will review and approve when appropriate. After having put into place the Data Transfer Agreement (plus Standard Contractual Clauses if receiving party is based outside the EU), the data can be shared through a secure, encrypted data sharing platform.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: To be determined

Access criteria: See publication policy described above.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Jul 25, 2025
StartEst.
Jan 1, 2027
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jul 1, 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Ethical committee in Europe did not provide approval
changed Oct 30, 2026
Enrollment
171 (estimated)→0 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Withdrawn
    Why stopped Ethical committee in Europe did not provide approval
    Enrollment 171 (estimated)→0 (actual)
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07084831
Lead sponsor
European Group for Research In Schizophrenia
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 1, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium

Start the discussion